ReviewArchives of pharmacal research2026
Bispecific antibody-drug conjugates: a modular blueprint for next-generation cancer therapeutics.
Review in Archives of pharmacal research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Circulating tumour cells for guiding antibody‒drug conjugate therapy: Role of artificial intelligence.Clinical and translational medicine · 2026Review
- Landscape of T-cell bispecific antibodies in cancer therapy: therapeutic strategies, challenges and future prospection.Molecular cancer · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Antibody-drug conjugates (ADCs) have rapidly developed over the past two decades as a class of targeted anticancer agents. These drugs deliver highly cytotoxic payloads conjugated to specific antibodies, targeting cancer cells and releasing the payload intracellularly to selectively kill tumor cells. However, in clinical practice, the therapeutic efficacy of ADCs is often inconsistent due to factors such as off-target effects, limited endocytosis rates, and the narrow specificity of the target. Bispecific antibody-drug conjugates (BsADCs) combine the characteristics of bispecific antibodies and ADCs, offering enhanced recognition capabilities and facilitating faster drug internalization, thereby potentially improving the therapeutic index and addressing some of the limitations of traditional ADCs. Moreover, BsADCs have the potential to treat not only cancer but also other diseases, positioning them as a future direction for ADC development.This review provides a brief overview of the structure of ADCs and current clinical research results. It focuses on the "toolbox" components of BsADCs and highlights examples of how each component is applied in the construction of BsADCs. This review also summarizes the key characteristics required for bispecific antibodies used in BsADC construction. Finally, a detailed analysis of the advantages of BsADCs over traditional ADCs is presented, along with a discussion of their future development. This paper aims to provide researchers interested in ADCs and BsADCs with detailed information on the composition, structure, and applications (including clinical data) of both ADCs and BsADCs, helping readers quickly understand the features and research progress of BsADCs and paving the way for further exploration in this field.
Indexed as
Identifiers
41656479What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.